Inspyr Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of promising, new therapeutics.
Inspyr is developing prodrug therapeutics for some of the most challenging diseases in oncology, harnessing a cutting-edge platform technology to deliver a cytotoxin safely and efficiently directly to tumors.
Mipsagargin, our lead agent, is in human clinical trials for patients with several different tumor types:
- Hepatocellular carcinoma, or liver cancer
- Oriental Femab Mining
- Glioblastoma, or brain cancer
- Prostate cancer
Our work is motivated by a commitment to innovation and helping patients. We combine our powerful insights and rigorous scientific methods to create new treatment options for patients.